No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1545-1548

  Kang, Seung Gul ^a   Choi, Jung Eun ^a   An, Hyonggin ^a   Lim, Se Won ^b   Lee, Heon Jeong ^a   Han, Changsu ^a   Kim, Yong Ku ^a   Kim, Seung Hyun ^a   Cho, Sung Nam ^c   Lee, Min Soo ^a   Joe, Sook Haeng ^a   Jung, In Kwa ^a   Kim, Leen ^a  

^a Korea University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Bugok National Hospital   (South Korea)

Author keywords

Brain derived neurotrophic factor; Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; METHIONINE; NEUROLEPTIC AGENT; VALINE;

ADULT; ARTICLE; BDNF GENE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ADULT; ALLELES; AMINO ACID SUBSTITUTION; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 47749114538     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.05.016     Document Type: Article

References (50)

1. Altar C.A., and DiStefano P.S. Neurotrophin trafficking by anterograde transport. Trends Neurosci 21 (1998) 433-437
2. Altar C.A., Boylan C.B., Jackson C., Hershenson S., Miller J., Wiegand S.J., et al. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci U S A 89 (1992) 11347-11351
3. Bai O., Chlan-Fourney J., Bowen R., Keegan D., and Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 71 (2003) 127-131
4. Bakker P.R., van Harten P.N., and van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 13 (2008) 544-556
5. Chen Q.Y., Chen Q., Feng G.Y., Wan C.L., Lindpaintner K., Wang L.J., et al. Association between the brain-derived neurotrophic factor (BDNF) gene and schizophrenia in the Chinese population. Neurosci Lett 397 (2006) 285-290
6. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., and Li X.M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 954 (2002) 11-20
7. Choi M.J., Kang R.H., Lim S.W., Oh K.S., and Lee M.S. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 1118 (2006) 176-182
8. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112 (2003) 257-269
9. Freudenreich O., and Goff D.C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106 (2002) 323-330
10. Fu Y., Fan C.H., Deng H.H., Hu S.H., Lv D.P., Li L.H., et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 27 (2006) 328-332
11. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU assessment manual for psychopharmacology (1976), U. S. Dept. of Health, Education, and Welfare 534-537
12. Han O.S., and Hong J.P. Structured clinical interview for DSM-IV axis I disorder-Korean version (2000), Hana Medical Publishing, Seoul
13. Itoh K., Hashimoto K., Kumakiri C., Shimizu E., and Iyo M. Association between brain-derived neurotrophic factor 196 G/A polymorphism and personality traits in healthy subjects. Am J Med Genet B Neuropsychiatr Genet 124 (2004) 61-63
14. Jeste D.V., and Caligiuri M.P. Tardive dyskinesia. Schizophr Bull 19 (1993) 303-315
15. Jonsson E.G., Edman-Ahlbom B., Sillen A., Gunnar A., Kulle B., Frigessi A., et al. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Prog Neuro-psychopharmacol Biol Psychiatry 30 (2006) 924-933
16. Kane J.M., Woerner M., and Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8 (1988) 52S-6S
17. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
18. Knusel B., Winslow J.W., Rosenthal A., Burton L.E., Seid D.P., Nikolics K., et al. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc Natl Acad Sci U S A 88 (1991) 961-965
19. Lee H.J. Pharmacogenetic studies investigating the adverse effects of antipsychotics. Psychiatry Invest 4 (2007) 66-75
20. Lee H.J., Kang R.H., Lim S.W., Paik J.W., Choi M.J., and Lee M.S. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and post-traumatic stress disorder. Stress Health 22 (2006) 115-119
21. Lee H.J., Kang S.G., Choi J.E., Paik J.W., Kim Y.K., Kim S.H., et al. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology 55 (2007) 47-51
22. Lee H.J., Kang S.G., Paik J.W., Lee M.S., Cho B.H., Park Y.M., et al. No evidence for an association between G protein β3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol Clin Exp 22 (2007) 501-504
23. Liou Y.J., Liao D.L., Chen J.Y., Wang Y.C., Lin C.C., Bai Y.M., et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 5 (2004) 243-251
24. Lohr J.B., and Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 31 (1995) 159-165
25. Lohr J.B., Kuczenski R., and Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17 (2003) 47-62
26. Macciardi F., Verga M., Cavallaro R., Pedrini S., Cohen S., and Smeraldi E. A genetic study of tardive dyskinesia in an Italian population of chronic schizophrenics. World congress on psychiatric genetics (1996), Psychiatric Genetics, San Francisco
27. Maisonpierre P.C., Le Beau M.M., Espinosa III R., Ip N.Y., Belluscio L., de la Monte S.M., et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10 (1991) 558-568
28. Mercader J.M., Ribasés M., Gratacòs M., Gonález J.R., Bayés M., et al. Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. Genes Brain Behav 6 (2007) 701-716
29. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 51 (2002) 133-136
30. Müller D.J., Schulze T.G., Knapp M., Held T., Krauss H., Weber T., et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 104 (2001) 375-379
31. Neves-Pereira M., Cheung J.K., Pasdar A., Zhang F., Breen G., Yates P., et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 10 (2005) 208-212
32. Nishio T., Furukawa S., Akiguchi I., and Sunohara N. Medial nigral dopamine neurons have rich neurotrophin support in humans. NeuroReport 9 (1998) 2847-2851
33. Parsian A., Sinha R., Racette B., Zhao J.H., and Perlmutter J.S. Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease. Parkinsonism Relat Disord 10 (2004) 213-219
34. Rosa A., Cuesta M.J., Fatjo-Vilas M., Peralta V., Zarzuela A., and Fananas L. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study. Am J Med Genet B Neuropsychiatr Genet 141 (2006) 135-138
35. Rosengarten H., Schweitzer J.W., and Friedhoff A.J. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 49 (1994) 663-667
36. Sachdev P.S. The current status of tardive dyskinesia. Aust N Z J Psychiatry 34 (2000) 355-369
37. Schooler N.R., and Kane J.M. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 39 (1982) 486-487
38. Segman R.H., Heresco-Levy U., Finkel B., Inbar R., Neeman T., Schlafman M., et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 152 (2000) 408-413
39. Segman R.H., Heresco-Levy U., Finkel B., Goltser T., Shalem R., Schlafman M., et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 6 (2001) 225-229
40. Shale H., and Tanner C. Pharmacological options for the management of dyskinesias. Drugs 52 (1996) 849-860
41. Steen V.M., Lovlie R., MacEwan T., and McCreadie R.G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 2 (1997) 139-145
42. Tamminga C.A., Dale J.M., Goodman L., Kaneda H., and Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl) 102 (1990) 474-478
43. Tan Y.L., Zhou D.F., and Zhang X.Y. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 74 (2005) 263-270
44. Tarsy D., and Baldessarini R.J. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 12 (1977) 431-450
45. Tarsy D., and Baldessarini R.J. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?. Mov Disord 21 (2006) 589-598
46. Watanabe Y., Muratake T., Kaneko N., Nunokawa A., and Someya T. No association between the brain-derived neurotrophic factor gene and schizophrenia in a Japanese population. Schizophr Res 84 (2006) 29-35
47. Weinhold P., Wegner J.T., and Kane J.M. Familial occurrence of tardive dyskinesia. J Clin Psychiatry 42 (1981) 165-166
48. Xu M.Q., St Clair D., Ott J., Feng G.Y., and He L. Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis. Schizophr Res 91 (2007) 6-13
49. Yassa R., and Ananth J. Familial tardive dyskinesia. Am J Psychiatry 138 (1981) 1618-1619
50. Yassa, R., Jeste, and D.V. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 18 (1992) 701-715